Cogent Biosciences, Inc.(COGT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

COGT Cogent Biosciences, Inc.

休市中 09-11 16:00:00 EDT

33.41

-0.67

-1.97%

盘后33.41

+0.000.00%

19:57 EDT

最高35.00	最低33.21	成交量171.58万
今开34.51	昨收34.08	日振幅5.25%
总市值57.97亿	流通市值55.74亿	总股本1.74亿
成交额5,763万	换手率1.03%	流通股本1.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"COGT","market":"US","secType":"STK","nameCN":"Cogent Biosciences, Inc.","latestPrice":33.41,"timestamp":1789156800000,"preClose":34.08,"halted":0,"volume":1715802,"hourTrading":{"tag":"盘后","latestPrice":33.41,"preClose":33.41,"latestTime":"19:57 EDT","volume":61420,"amount":2052005.57,"timestamp":1789171029508,"change":0,"changeRate":0,"amplitude":0.001796},"delay":0,"changeRate":-0.01965962441314559,"floatShares":166832314,"shares":173524982,"eps":-2.16,"marketStatus":"休市中","change":-0.67,"latestTime":"09-11 16:00:00 EDT","open":34.51,"high":35,"low":33.21,"amount":57634712.281476006,"amplitude":0.052523,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.16,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1522296000000,"exchange":"NASDAQ","adjPreClose":34.08,"preHourTrading":{"tag":"盘前","latestPrice":34.33,"preClose":34.08,"latestTime":"08:46 EDT","volume":1403,"amount":47964.971305,"timestamp":1789130796974,"change":0.25,"changeRate":0.007336,"amplitude":0.023474},"postHourTrading":{"tag":"盘后","latestPrice":33.41,"preClose":33.41,"latestTime":"19:57 EDT","volume":61420,"amount":2052005.57,"timestamp":1789171029508,"change":0,"changeRate":0,"amplitude":0.001796},"volumeRatio":1.0527272278114281,"impliedVol":0.3776,"impliedVolPercentile":0.0279},"requestUrl":"/m/hq/s/COGT","defaultTab":"news","newsList":[{"id":"1107575074","title":"Cogent Biosciences将向Hovione采购Bezuclastinib产品最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575074","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107575074?lang=zh_cn&edition=full","pubTime":"2026-09-03 04:14","pubTimestamp":1788380059,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 已通过SEC文件披露，计划向Hovione采购Bezuclastinib产品的指定最低比例份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4505","BK4139","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126702774","title":"Cogent Biosciences协议生效：为期五年，自动续约两年——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126702774","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126702774?lang=zh_cn&edition=full","pubTime":"2026-09-03 04:13","pubTimestamp":1788379990,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 的某项协议已正式生效，其初始期限设定为五年。根据美国证券交易委员会（SEC）的备案文件，该协议条款中包含自动续约机制——每当五年期限届满，协议将自动延长两年。这一续约安排，为合作双方的长期关系提供了延续性预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4139","LFSC","BK4505","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189948002","title":"Cogent Biosciences拟通过Guggenheim Securities发行高达4亿美元普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1189948002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189948002?lang=zh_cn&edition=full","pubTime":"2026-08-11 05:19","pubTimestamp":1786396748,"startTime":"0","endTime":"0","summary":"Cogent Biosciences公司——根据其向美国证券交易委员会提交的文件显示，该公司可能通过Guggenheim Securities进行高达4亿美元的普通股公开发售。这一动向，无疑为市场注入了新的关注点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LFSC","CANC","COGT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173801167","title":"Cogent Biosciences第二季度净亏损9640.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173801167","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173801167?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:15","pubTimestamp":1786364138,"startTime":"0","endTime":"0","summary":"Cogent Biosciences（股票代码：COGT）发布了第二季度财报。数据显示，公司在运营方面出现了1.02638亿美元的亏损，由此导致净亏损达9640.5万美元。这一财务表现反映出公司当期面临的挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","COGT","BK4505","CANC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155329065","title":"Cogent Biosciences联合疗法在GIST患者中展现统计学显著无进展生存期优势","url":"https://stock-news.laohu8.com/highlight/detail?id=1155329065","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155329065?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:07","pubTimestamp":1780142856,"startTime":"0","endTime":"0","summary":"Cogent Biosciences公司宣布，其药物Bezuclastinib的联合疗法在胃肠道间质瘤（GIST）患者中取得了统计学上显著的无进展生存期（PFS）优势。这一积极数据为该公司针对这一难治性癌症的研发管线带来了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","COGT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157043128","title":"Cogent Biosciences 公布PEAK III期试验详细临床数据：Bezuclastinib联合舒尼替尼治疗胃肠道间质瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1157043128","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157043128?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:01","pubTimestamp":1780142467,"startTime":"0","endTime":"0","summary":"Cogent Biosciences 公司在2026年美国临床肿瘤学会年会上，公布了其PEAK III期试验的详细临床数据。该试验评估了Bezuclastinib与舒尼替尼联合疗法，用于治疗胃肠道间质瘤患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167800219","title":"Cogent Biosciences宣布FDA接受其新药申请，针对贝祖克拉替尼联合舒尼替尼治疗胃肠道间质瘤患者获得优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1167800219","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167800219?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:01","pubTimestamp":1779969687,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.（COGT）宣布，美国食品药品监督管理局（FDA）已接受其新药申请（NDA），并对贝祖克拉替尼（bezuclastinib）联合舒尼替尼（sunitinib）用于治疗胃肠道间质瘤（GIST）患者的方案授予优先审评资格。\n这一决定标志着该药物组合在监管审批进程中迈出了关键一步。优先审评资格的授予通常意味着FDA认为该疗法有潜力在治疗严重疾病方面提供显著优势。对于患有GIST的患者群体而言，这可能是一个重要的治疗新选择。\n公司表示，将全力配合FDA的审评流程，以期尽快将这一潜在疗法带给有需要的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156991216","title":"Cogent Biosciences, Inc. 2026年第一季度末现金储备达8.664亿美元，可支撑运营至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1156991216","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156991216?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:10","pubTimestamp":1777983024,"startTime":"0","endTime":"0","summary":"生物科技公司Cogent Biosciences, Inc.最新财务数据显示，截至2026年第一季度末，公司持有现金及现金等价物总额达8.664亿美元。这一资金规模预计能为企业当前研发与商业化进程提供充足支持，至少可维持正常运营至2028年。\n强劲的现金储备为该公司核心候选药物BEZ-235的临床推进提供了坚实保障。该资金水平显著高于同业生物科技企业均值，反映出投资人对公司技术平台与管线价值的认可。管理层表示将延续审慎的资本配置策略，重点投入最具潜力的肿瘤靶向疗法开发领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189701379","title":"Cogent Biosciences宣布FDA受理Bezuclastinib治疗非晚期系统性肥大细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1189701379","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189701379?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:38","pubTimestamp":1773664686,"startTime":"0","endTime":"0","summary":"Cogent Biosciences Inc近日宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的上市申请。根据FDA的处方药使用者付费法案（PDUFA），该药物的审评截止日期定为2026年12月30日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135972760","title":"Cogent Biosciences早盘大涨7.2% 旗下罕见病药物申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1135972760","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135972760?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:37","pubTimestamp":1773664656,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.股价在盘前交易中强势上扬7.2%，此前美国食品药品监督管理局（FDA）已正式受理其针对一款罕见病治疗药物的新药申请，并将启动审评流程。这一关键监管进展为该公司核心产品的商业化之路扫清了首个重要障碍，显著提振了市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106712714","title":"Cogent Biosciences宣布FDA受理Bezuclastinib治疗非晚期系统性肥大细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1106712714","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106712714?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:37","pubTimestamp":1773664627,"startTime":"0","endTime":"0","summary":"Cogent Biosciences宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的新药申请。这一重要进展标志着该药物在监管审批流程中迈出了关键一步，为非晚期系统性肥大细胞增多症患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COGT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518273740","title":"Cogent Biosciences, Inc.盘中异动 早盘快速下挫5.14%报6.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518273740?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:34","pubTimestamp":1741617259,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时34分，Cogent Biosciences, Inc.股票出现异动，股价大幅跳水5.14%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3473.08%、737.01%、547.82%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223419a26a3cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223419a26a3cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517588467","title":"Cogent Biosciences(COGT.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价17.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517588467","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517588467?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:32","pubTimestamp":1741386747,"startTime":"0","endTime":"0","summary":"Cogent Biosciences(COGT.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价17.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08063248605336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517192712","title":"Cogent Biosciences, Inc.盘中异动 股价大跌5.02%报7.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517192712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517192712?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:59","pubTimestamp":1741291182,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时59分，Cogent Biosciences, Inc.股票出现异动，股价大幅下跌5.02%。截至发稿，该股报7.29美元/股，成交量28.4949万股，换手率0.25%，振幅5.35%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.24%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307035942989eecbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307035942989eecbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517173928","title":"Cogent Biosciences, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517173928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517173928?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:42","pubTimestamp":1741200158,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时42分，Cogent Biosciences, Inc.股票出现波动，股价大幅上涨5.02%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.37%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Marker Therapeutics, Inc.涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为952.54%、306.39%、303.63%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Marker Therapeutics, Inc.，振幅分别为82.59%、54.27%、50.73%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306024239a2610cd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306024239a2610cd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190107990","title":"异动解读 | Cogent Biosciences, Inc.盘中大跌5.05%,暂时原因不明","url":"https://stock-news.laohu8.com/highlight/detail?id=1190107990","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190107990?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:46","pubTimestamp":1741020385,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.(COGT)今日盘中股价大跌5.05%,引发市场广泛关注。\n根据公开新闻报道,该股盘中出现大幅下跌,最低报7.15美元/股,振幅6.24%。但目前暂时没有明确的消息报道可以解释其股价下跌的具体原因。\n公司主要从事生物技术领域,为遗传定义的疾病开发精准疗法。其主要产品CGT9486是一种旨在抑制导致系统性肥大细胞增多症和晚期胃肠道间质瘤的KIT激酶突变的药物。目前有待进一步关注公司动向,以明确导致股价大幅波动的原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Cogent Biosciences, Inc.盘中大跌5.05%,暂时原因不明","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516655976","title":"Cogent Biosciences, Inc.盘中异动 临近午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516655976","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516655976?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:36","pubTimestamp":1741019794,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时36分，Cogent Biosciences, Inc.股票出现异动，股价快速下跌5.05%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3884.93%、173.17%、141.71%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、90.70%、70.53%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003635abe65a63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003635abe65a63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516379238","title":"Cogent Biosciences, Inc.盘中异动 大幅上涨5.15%报7.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516379238?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:05","pubTimestamp":1740758738,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时05分，Cogent Biosciences, Inc.股票出现波动，股价大幅上涨5.15%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2134.68%、472.61%、355.99%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Bioxcel Therapeutics, Inc.，振幅分别为46.60%、43.95%、41.62%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000539a258194e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000539a258194e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514386166","title":"Cogent Biosciences, Inc.盘中异动 早盘大幅上涨5.22%报7.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514386166","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514386166?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:50","pubTimestamp":1740667824,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时50分，Cogent Biosciences, Inc.股票出现波动，股价快速上涨5.22%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pds Biotechnology Corporation、Nutriband Inc C/Wts 涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为472.71%、96.28%、85.32%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Biorestorative Therapies, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为59.93%、30.36%、21.99%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272250259632b4e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272250259632b4e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514740861","title":"Cogent Biosciences, Inc.盘中异动 急速下跌5.01%报6.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514740861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514740861?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:29","pubTimestamp":1740598157,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时29分，Cogent Biosciences, Inc.股票出现异动，股价快速跳水5.01%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.54%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Nkgen Biotech Inc C/Wts 31/05/2028涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6547.79%、305.81%、259.14%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为194.07%、81.11%、54.00%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270329179893e051&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270329179893e051&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COGT","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogentbio.com","stockEarnings":[{"period":"1week","weight":-0.0388},{"period":"1month","weight":-0.1429},{"period":"3month","weight":0.0094},{"period":"6month","weight":-0.0174},{"period":"1year","weight":1.6081},{"period":"ytd","weight":-0.0594}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cogent Biosciences, Inc.于2014年3月根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司，专注于开发针对遗传性疾病的精确疗法。该公司的方法是设计合理的精准疗法，治疗疾病的根本原因，改善患者的生活。该公司最先进的项目是bezuclastinib，也称为CGT9486，这是一种高度选择性的酪氨酸激酶抑制剂，旨在有效抑制KIT D816V突变以及KIT外显子17中的其他突变。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.010222},{"month":2,"riseRate":0.25,"avgChangeRate":-0.008843},{"month":3,"riseRate":0.375,"avgChangeRate":-0.05068},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.064438},{"month":5,"riseRate":0.555556,"avgChangeRate":0.044683},{"month":6,"riseRate":0.666667,"avgChangeRate":0.134003},{"month":7,"riseRate":0.777778,"avgChangeRate":0.617081},{"month":8,"riseRate":0.555556,"avgChangeRate":0.1009},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.103599},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011089},{"month":11,"riseRate":0.125,"avgChangeRate":0.046358},{"month":12,"riseRate":0.25,"avgChangeRate":-0.095771}],"exchange":"NASDAQ","name":"Cogent Biosciences, Inc.","nameEN":"Cogent Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cogent Biosciences, Inc.(COGT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cogent Biosciences, Inc.(COGT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cogent Biosciences, Inc.,COGT,Cogent Biosciences, Inc.股票,Cogent Biosciences, Inc.股票老虎,Cogent Biosciences, Inc.股票老虎国际,Cogent Biosciences, Inc.行情,Cogent Biosciences, Inc.股票行情,Cogent Biosciences, Inc.股价,Cogent Biosciences, Inc.股市,Cogent Biosciences, Inc.股票价格,Cogent Biosciences, Inc.股票交易,Cogent Biosciences, Inc.股票购买,Cogent Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cogent Biosciences, Inc.(COGT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cogent Biosciences, Inc.(COGT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}